CLRB · Cellectar Biosciences, Inc. · Share Buybacks
$2.37
-0.05 (-1.87%)
At close · Sep 9
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates it will be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.”View the 10-Q filed Aug 13, 2026
Market Cap
$22.78M
Shares
9.45M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2014-03-31 YTD | $0 | 10-Q, filed 2014-05-14 |
| 2013-12-31 | $0 | 10-K, filed 2014-03-19 |
| 2012-12-31 | $0 | 10-K, filed 2014-03-19 |
| 2011-12-31 | $0 | 10-K, filed 2013-03-28 |
Key facts
CIK
1279704
CUSIP
15117F880
13F (30d)
23 filings
23 filers
Visit website
Investor relations